Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C).
Other conference paper


Full Text

Times Cited
Web of Science1WOS source URL (as at 24/11/2020) Click here for the latest count

Other information
All Author(s) ListMok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Wen W, Tsai J, Truman M, Klughammer B, Wu L
Name of ConferenceAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Start Date of Conference31/05/2013
End Date of Conference04/06/2013
Place of ConferenceChicago
Country/Region of ConferenceUnited States of America
Journal nameJournal of Clinical Oncology
Detailed descriptionorganized by American Society of Clinical Oncology,
Year2013
Month5
Day20
Volume Number31
Issue Number15
PublisherAMER SOC CLINICAL ONCOLOGY
ISSN0732-183X
eISSN1527-7755
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2020-25-11 at 03:08